GlassScriptPhysician profile
Palak Patel
NPI 1275196412
$1,178.30
in general payments reported to CMS, 2019-2025
11 companies · $637 in 2025
The $637 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.67 · 2024: $462 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.06 |
| Education | $221.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $328.98 | 2024-2025 | Impella |
| Medtronic, INC. | $221.24 | 2025 | Resolute Onyx |
| Astrazeneca Pharmaceuticals LP | $172.30 | 2024-2025 | Wainua |
| Pfizer INC. | $151.42 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $128.56 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $47.17 | 2024 | |
| Chiesi USA, INC. | $34.65 | 2025 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $30.12 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.96 | 2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $16.96 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $16.94 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.